Difference between revisions of "Sakamuri D, et al. Mol. Cancer Ther. (2018) cited as Ref 635 in DOI: 10.1038/s41392-020-0110-5 (Q9898)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 17, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers (English) | ||
| Property / title: Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:05, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Sakamuri D, et al. Mol. Cancer Ther. (2018) cited as Ref 635 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Sakamuri D
0 references
2018
0 references
Mol. Cancer Ther.
0 references
17
0 references
Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers (English)
0 references
